Coverage
-
June 23, 2017
Clovis Oncology Inc. has agreed to pay $142 million in cash and stock to settle a proposed class action that claimed the company inflated its stock price by misleading investors about the efficacy of a cancer drug, shareholders told a Colorado federal court Thursday.
3 other articles on this case.
View all »